ALVO Stock Overview
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Alvotech Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,645.00 |
| 52 Week High | US$2,500.00 |
| 52 Week Low | US$1,455.00 |
| Beta | -0.15 |
| 1 Month Change | -2.08% |
| 3 Month Change | 9.30% |
| 1 Year Change | 6.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 23.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALVO | IS Biotechs | IS Market | |
|---|---|---|---|
| 7D | -2.7% | 0% | 0% |
| 1Y | 6.1% | 0% | 0% |
Return vs Industry: ALVO underperformed the IS Biotechs industry which returned 11.4% over the past year.
Return vs Market: ALVO underperformed the IS Market which returned 10.5% over the past year.
Price Volatility
| ALVO volatility | |
|---|---|
| ALVO Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in IS Market | 0% |
| 10% least volatile stocks in IS Market | 0% |
Stable Share Price: ALVO's share price has been volatile over the past 3 months compared to the IS market.
Volatility Over Time: ALVO's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of IS stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 999 | Robert Wessman | www.alvotech.com |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Alvotech Fundamentals Summary
| ALVO fundamental statistics | |
|---|---|
| Market cap | ISK 500.33b |
| Earnings (TTM) | -ISK 61.48b |
| Revenue (TTM) | ISK 54.86b |
9.1x
P/S Ratio-8.1x
P/E RatioIs ALVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALVO income statement (TTM) | |
|---|---|
| Revenue | US$393.92m |
| Cost of Revenue | US$161.40m |
| Gross Profit | US$232.52m |
| Other Expenses | US$673.98m |
| Earnings | -US$441.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 59.03% |
| Net Profit Margin | -112.07% |
| Debt/Equity Ratio | -299.1% |
How did ALVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alvotech is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Peter Verdult | Citigroup Inc |